Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Does the market know something???
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(34)
•••
Comment by Newinvestor68on Jun 17, 2020 8:14pm
89 Views
Post# 31162770

RE:RE:RE:RE:RE:Does the market know something???

RE:RE:RE:RE:RE:Does the market know something???

Source about him carrying about stock price? No source but tell me what good has happened with this company? Nothing, the way they keep diluting the shares leads me to believe that.

I absolutely don't know that much about the ins and outs of running a public company but based on the success of Kalytera Rob knows how to pretty up press releases and move things around but not how to run a successful company. 

Read the press releases  they change slightly and it there is very little that comes of them.

lastly lighten up, I have shares in Kalytera and as much as I would love to believe something will happen I seriously doubt we will have anything to celebrate. Oh how I hope I am wrong but look at how Kalytera, the Salzman group and a few others have been promoting each other for years. It looks like they keep making announcements to add false credibility to each other's company. 

 

Save your arrogant reply for the day that we all become rich from Kalytera and I will save mine for the day we have nothing left. 

please enlighten me, give me an approximate month and year that you believe this company will actually accomplish something besides dilution. I will not reply to you until that date. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities